Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Feature|Articles|July 9, 2026
Hematologists Detail Practice-Shaping Data That Emerged at EHA 2026 (VIDEO)
Author(s)Chris Ryan
Fact checked by: Riley Kandel
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
Advertisement
Advertisement
Pivotal data shared across multiple myeloma, large B-cell lymphoma (LBCL), and myeloproliferative neoplasms (MPNs) took the spotlight during the
Related to this article
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
Advertisement
Advertisement